TYRA BIOSCIENCES, INC.
TYRA
20.39
+0.15
+0.74%
TYRA BIOSCIENCES, INC.
US · TYRA
#3032 by market cap
Listed 2021
20.39
+0.15
+0.74%
Live - 5344 symbols - heartbeat 462s ago
· 2026-10-07 19:54
After-hours
20.39
0.00%
- Market cap
- 1.40B
- P/E (TTM)i
- -8.53
- P/Bi
- 3.96
- EPSi
- -2.01
- Div yieldi
- 0.00%
- 52W posi
- 26%
Reader sentiment
Are you bullish or bearish on TYRA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.33M | 2.09M | 5.65M | 15.92M | 17.43M | 24.10M | 29.83M |
| Research & development | 1.79M | 7.20M | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Operating profit | -3.12M | -9.30M | -26.29M | -58.93M | -79.95M | -104.18M | -132.76M |
| Pretax profit | -4.07M | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -4.07M | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Basic EPS | 0 | 0 | -2 | -1 | -2 | -2 | -2 |
| Diluted EPS | -0.40 | -0.42 | -1.91 | -1.32 | -1.62 | -1.51 | -2.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.89M | 7.14M | 7.48M | 8.33M | 8.53M | 9.81M |
| Research & development | 24.96M | 24.31M | 25.47M | 28.19M | 33.47M | 39.20M |
| Operating profit | -31.85M | -31.45M | -32.94M | -36.52M | -42.00M | -49.00M |
| Pretax profit | -28.15M | -28.10M | -29.87M | -33.83M | -39.31M | -45.56M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -28.15M | -28.10M | -29.87M | -33.83M | -39.31M | -45.56M |
| Basic EPS | 0 | 0 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.47 | -0.47 | -0.50 | -0.57 | -0.64 | -0.69 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 127.00K | 15.28M | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Cash & ST investments | 108.00K | 15.22M | 302.18M | 251.21M | 203.47M | 341.44M | 256.00M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 528.00K | 16.01M | 306.70M | 266.18M | 225.86M | 363.56M | 282.61M |
| Total current liabilities | 5.16M | 1.86M | 3.62M | 5.70M | 15.33M | 14.59M | 18.09M |
| Short-term debt | 139.00K | 142.00K | 202.00K | 140.00K | 280.00K | 412.00K | 472.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 5,269,000.00 | 29,649,000.00 | 4,964,000.00 | 8,352,000.00 | 21,595,000.00 | 20,407,000.00 | 23,432,000.00 |
| Total equity | -4.74M | -13.64M | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Retained earnings | -4.74M | -14.08M | -40.37M | -95.70M | -164.83M | -251.31M | -371.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 324.57M | 302.16M | 281.22M | 265.45M | 394.61M | 366.97M |
| Cash & ST investments | 318.94M | 296.27M | 274.92M | 256.00M | 383.47M | 353.94M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 343.48M | 321.50M | 301.85M | 282.61M | 412.04M | 383.36M |
| Total current liabilities | 14.25M | 13.77M | 15.88M | 18.09M | 19.26M | 24.62M |
| Short-term debt | 426.00K | 441.00K | 456.00K | 472.00K | 488.00K | 504.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 19,942,000.00 | 19,352,000.00 | 21,342,000.00 | 23,432,000.00 | 24,465,000.00 | 29,698,000.00 |
| Total equity | 323.53M | 302.15M | 280.51M | 259.18M | 387.58M | 353.66M |
| Retained earnings | -279.46M | -307.56M | -337.42M | -371.26M | -410.56M | -456.12M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.62M | -7.76M | -23.75M | -50.29M | -50.14M | -69.77M | -95.14M |
| Depreciation & amortization | 8.00K | 47.00K | 140.00K | 296.00K | 357.00K | 519.00K | 546.00K |
| Free cash flow | -2.64M | -8.08M | -24.41M | -50.84M | -50.91M | -70.44M | -95.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 181.22M | -- | 0 | 199.58M | 0 |
| Ending cash balance | 108.00K | 15.47M | 302.43M | 252.21M | 59.01M | 92.97M | 78.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -25.46M | -23.68M | -22.38M | -23.62M | -32.57M | -31.08M |
| Depreciation & amortization | 143.00K | 140.00K | 131.00K | 132.00K | 138.00K | 138.00K |
| Free cash flow | -25.47M | -23.71M | -22.42M | -23.68M | -32.66M | -31.14M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 147.85M | 0 |
| Ending cash balance | 101.72M | 99.49M | 62.95M | 78.39M | 85.96M | 74.84M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -18.25 | -19.77 | -29.92 | -31.60 | -39.83 |
| ROA %i | -769.89 | -112.90 | -16.30 | -19.31 | -28.10 | -29.34 | -37.13 |
| ROIC %i | -- | -- | -18.18 | -20.94 | -33.95 | -37.20 | -43.22 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -27.88 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.02 | 8.22 | 84.09 | 45.13 | 13.80 | 23.81 | 14.67 |
| Quick ratioi | 0.02 | 8.19 | 83.57 | 44.06 | 13.27 | 23.40 | 14.15 |
| Debt / assetsi | 47.92 | 0.89 | 0.39 | 0.99 | 2.88 | 1.71 | 2.06 |
| LT debt / equityi | -- | -- | 0.33 | 0.96 | 3.04 | 1.69 | 2.06 |
| Interest coveragei | -4,064.00 | -9,335.00 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -27.04 | -31.21 | -34.75 | -39.83 | -36.87 | -45.31 |
| ROA %i | -25.78 | -29.65 | -32.73 | -37.13 | -34.71 | -42.15 |
| ROIC %i | -31.32 | -35.22 | -38.47 | -43.22 | -39.54 | -48.08 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 22.78 | 21.94 | 17.71 | 14.67 | 20.49 | 14.91 |
| Quick ratioi | 22.39 | 21.52 | 17.31 | 14.15 | 19.91 | 14.38 |
| Debt / assetsi | 1.78 | 1.87 | 1.96 | 2.06 | 1.38 | 1.46 |
| LT debt / equityi | 1.76 | 1.85 | 1.95 | 2.06 | 1.34 | 1.44 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.